肿瘤科指南

订阅

MedSci主页 / 所有栏目 / 肿瘤科指南

2017 南亚实践共识建议：三阴乳腺癌的新辅助化疗

2017-05-01 国外肿瘤科相关专家小组（统称） South Asian J Cancer. 2018 Apr-Jun;7(2):156-158.

三阴乳腺癌新辅助化疗

新辅助化疗主要在局部进展期乳腺癌或不能手术切除的乳腺癌患者中应用，三阴乳腺癌也可以应用新辅助化疗。本文主要针对新辅助化疗在三阴乳腺癌中的应用提供指导建议。

中文标题：

2017 南亚实践共识建议：三阴乳腺癌的新辅助化疗

英文标题：

Practical consensus recommendations for neo‑adjuvant chemotherapy in triple negative breast cancer

发布机构：

国外肿瘤科相关专家小组（统称）

发布日期：

2017-05-01

简要介绍：

新辅助化疗主要在局部进展期乳腺癌或不能手术切除的乳腺癌患者中应用，三阴乳腺癌也可以应用新辅助化疗。本文主要针对新辅助化疗在三阴乳腺癌中的应用提供指导建议。 

拓展指南：与乳腺癌相关指南：

相关资料下载：
[AttachmentFileName(sort=100, fileName=2017 南亚实践共识建议：三阴乳腺癌的新辅助化疗)] GetToolGuiderByIdResponse(projectId=1, id=4135b1c001588679, title=2017 南亚实践共识建议：三阴乳腺癌的新辅助化疗, enTitle=Practical consensus recommendations for neo‑adjuvant chemotherapy in triple negative breast cancer, guiderFrom=South Asian J Cancer. 2018 Apr-Jun;7(2):156-158., authorId=null, author=, summary=新辅助化疗主要在局部进展期乳腺癌或不能手术切除的乳腺癌患者中应用，三阴乳腺癌也可以应用新辅助化疗。本文主要针对新辅助化疗在三阴乳腺癌中的应用提供指导建议。 , cover=, journalId=null, articlesId=null, associationId=887, associationName=国外肿瘤科相关专家小组（统称）, associationIntro=null, copyright=0, guiderPublishedTime=Mon May 01 00:00:00 CST 2017, originalUrl=, linkOutUrl=, content=<div>新辅助化疗主要在局部进展期乳腺癌或不能手术切除的乳腺癌患者中应用，三阴乳腺癌也可以应用新辅助化疗。本文主要针对新辅助化疗在三阴乳腺癌中的应用提供指导建议。 </div> <div><br> </div>拓展指南：<strong>与<font color=red>乳腺癌</font>相关指南：</strong><br><ul><li><a href="http://www.medsci.cn/guideline/show_article.do?id=7f8411c00158e0dc" title="NCCN临床实践指南：乳腺癌筛查和诊断（2018.V1）" target=_blank>NCCN临床实践指南：乳腺癌筛查和诊断（2018.V1）</a></li> <li><a href="http://www.medsci.cn/guideline/show_article.do?id=aee421c00158a095" title="NCCN临床实践指南：降低乳腺癌风险（2018.V2）" target=_blank>NCCN临床实践指南：降低乳腺癌风险（2018.V2）</a></li> <li><a href="http://www.medsci.cn/guideline/show_article.do?id=9e34e1c0015ea7be" title="中国蒽环类药物治疗乳腺癌专家共识" target=_blank>中国蒽环类药物治疗乳腺癌专家共识</a></li> <li><a href="http://www.medsci.cn/guideline/show_article.do?id=b25b61c0015ea1c3" title="NCCN临床实践指南：乳腺癌（2018.V1）" target=_blank>NCCN临床实践指南：乳腺癌（2018.V1）</a></li> <li><a href="http://www.medsci.cn/guideline/show_article.do?id=6895d1c00155e814" title="NCCN临床实践指南：乳腺癌（2017.V4）" target=_blank>NCCN临床实践指南：乳腺癌（2017.V4）</a></li> 更多信息请点击：<a href="http://www.medsci.cn/guideline/list.do?q=%E4%B9%B3%E8%85%BA%E7%99%8C" target=_blank>有关乳腺癌更多指南</a></ul>, tagList=[TagDto(tagId=3673, tagName=三阴乳腺癌), TagDto(tagId=801, tagName=新辅助化疗)], categoryList=[CategoryDto(categoryId=5, categoryName=肿瘤科, tenant=100), CategoryDto(categoryId=89, categoryName=乳腺癌, tenant=100), CategoryDto(categoryId=21100, categoryName=达仁堂循证e学界, tenant=100)], articleKeywordId=null, articleKeyword=null, articleKeywordNum=null, guiderKeywordId=null, guiderKeyword=null, guiderKeywordNum=null, haveAttachments=1, attachmentList=null, guiderType=0, guiderArea=共识, guiderLanguage=0, guiderRegion=4, opened=0, paymentType=null, paymentAmount=10, recommend=0, recommendEndTime=null, sticky=0, stickyEndTime=null, allHits=8261, appHits=293, showAppHits=0, pcHits=6825, showPcHits=1687, likes=244, shares=2, comments=2, approvalStatus=1, publishedTime=Mon May 07 17:37:41 CST 2018, publishedTimeString=2017-05-01, pcVisible=1, appVisible=1, editorId=2020535, editor=qiushida2, waterMark=0, formatted=0, memberCards=[], isPrivilege=0, deleted=0, version=1, createdBy=null, createdName=qiushida2, createdTime=Mon May 07 17:37:41 CST 2018, updatedBy=null, updatedName=null, updatedTime=Fri Jan 05 16:20:41 CST 2024, courseDetails=[], otherVersionGuiders=[], isGuiderMember=false, ipAttribution=, attachmentFileNameList=[AttachmentFileName(sort=100, fileName=2017 南亚实践共识建议：三阴乳腺癌的新辅助化疗)])
2017 南亚实践共识建议：三阴乳腺癌的新辅助化疗
下载请点击：
评论区 (2)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=326771, encodeId=a1ba326e7168, content=学习了.谢谢分享, beContent=null, objectType=guider, channel=null, level=null, likeNumber=111, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1bb241978, createdName=phoebeyan520, createdTime=Mon Jun 25 00:59:49 CST 2018, time=2018-06-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=312902, encodeId=79a93129027e, content=谢谢老师的讲解, beContent=null, objectType=guider, channel=null, level=null, likeNumber=107, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mONcle9pic3zMoyicyo6ia9f4IuLQAwZoxD6Hx4ibd5CMcOCYhStY6oDibbKK6O2X8iaicldO5ib8j1iapOIobIKCGiczU2A/0, createdBy=56251941490, createdName=虈亣靌, createdTime=Mon May 07 19:05:17 CST 2018, time=2018-05-07, status=1, ipAttribution=)]
    2018-06-25 phoebeyan520

    学习了.谢谢分享

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=326771, encodeId=a1ba326e7168, content=学习了.谢谢分享, beContent=null, objectType=guider, channel=null, level=null, likeNumber=111, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1bb241978, createdName=phoebeyan520, createdTime=Mon Jun 25 00:59:49 CST 2018, time=2018-06-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=312902, encodeId=79a93129027e, content=谢谢老师的讲解, beContent=null, objectType=guider, channel=null, level=null, likeNumber=107, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mONcle9pic3zMoyicyo6ia9f4IuLQAwZoxD6Hx4ibd5CMcOCYhStY6oDibbKK6O2X8iaicldO5ib8j1iapOIobIKCGiczU2A/0, createdBy=56251941490, createdName=虈亣靌, createdTime=Mon May 07 19:05:17 CST 2018, time=2018-05-07, status=1, ipAttribution=)]
    2018-05-07 虈亣靌

    谢谢老师的讲解

    0